Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS.

Vaccine. 2011 Nov 28;29(51):9563-72. doi: 10.1016/j.vaccine.2011.08.089.

2.

An alternative renewable source of squalene for use in emulsion adjuvants.

Brito LA, Chan M, Baudner B, Gallorini S, Santos G, O'Hagan DT, Singh M.

Vaccine. 2011 Aug 26;29(37):6262-8. doi: 10.1016/j.vaccine.2011.06.067.

PMID:
21723355
3.

Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.

Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL, Morton KE, Laurencot CM, Sherry RM.

J Immunother. 2010 Jul-Aug;33(6):626-9. doi: 10.1097/CJI.0b013e3181dac9de.

4.

Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions.

Fox CB, Lin S, Sivananthan SJ, Dutill TS, Forseth KT, Reed SG, Vedvick TS.

Pharm Dev Technol. 2011 Oct;16(5):511-9. doi: 10.3109/10837450.2010.495397.

PMID:
20550484
5.

The spectrum of plant and animal sterols in different oil-derived intravenous emulsions.

Forchielli ML, Bersani G, Tala S, Grossi G, Puggioli C, Masi M.

Lipids. 2010 Jan;45(1):63-71. doi: 10.1007/s11745-009-3371-x.

PMID:
20049583
6.

Squalene: A natural triterpene for use in disease management and therapy.

Reddy LH, Couvreur P.

Adv Drug Deliv Rev. 2009 Dec 17;61(15):1412-26. doi: 10.1016/j.addr.2009.09.005. Review.

PMID:
19804806
7.

Squalene emulsions for parenteral vaccine and drug delivery.

Fox CB.

Molecules. 2009 Sep 1;14(9):3286-312. doi: 10.3390/molecules14093286. Review.

8.

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.

Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, Evers T, Mompoint F, Vedvick TS, Bertholet S, Coler RN, Reed SG.

Vaccine. 2009 Oct 9;27(43):5956-63. doi: 10.1016/j.vaccine.2009.07.081.

PMID:
19679214
9.

MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, Singh M, Hawkins LD, Wack A, O'Hagan DT.

Pharm Res. 2009 Jun;26(6):1477-85. doi: 10.1007/s11095-009-9859-5.

PMID:
19255727
10.

Half-dose influenza vaccine: stretching the supply or wasting it?

Falsey AR.

Arch Intern Med. 2008 Dec 8;168(22):2402-3. doi: 10.1001/archinte.168.22.2402. No abstract available.

PMID:
19064820
11.

Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions.

Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick TS.

Colloids Surf B Biointerfaces. 2008 Aug 1;65(1):98-105. doi: 10.1016/j.colsurfb.2008.03.003.

PMID:
18440205
12.

Critical review of techniques and methodologies for characterization of emulsion stability.

McClements DJ.

Crit Rev Food Sci Nutr. 2007;47(7):611-49. Review.

PMID:
17943495
13.
14.
15.

Cell death induced by vaccine adjuvants containing surfactants.

Yang YW, Wu CA, Morrow WJ.

Vaccine. 2004 Mar 29;22(11-12):1524-36.

PMID:
15063578
16.

Degradation of kinetically-stable o/w emulsions.

Capek I.

Adv Colloid Interface Sci. 2004 Mar 19;107(2-3):125-55.

PMID:
15026289
18.

Stability criteria for emulsions.

Bibette J, Morse DC, Witten TA, Weitz DA.

Phys Rev Lett. 1992 Oct 19;69(16):2439-2442. No abstract available.

PMID:
10046485
19.

Interfacial properties as stability predictors of lecithin-stabilized perfluorocarbon emulsions.

Yoon JK, Burgess DJ.

Pharm Dev Technol. 1996 Dec;1(4):333-41.

PMID:
9552317
20.

Phospholipids as Emulsion Stabilizers

Kabalnov A, Tarara T, Arlauskas R, Weers J.

J Colloid Interface Sci. 1996 Dec 1;184(1):227-35.

PMID:
8954658
Items per page

Supplemental Content

Support Center